TICKERNERD
Menu
CAICAIHealthcare · Biotechnology

CAI Stock Forecast: Caris Life Sciences, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$30
+2.46% on the day

The 14 Wall Street analysts covering Caris Life Sciences, Inc. hold a median 12-month price target of $33 — +9.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 14 Oct 2026 — in the lower half.

Market cap
$8.5B
Ticker Nerd rank
41 / 100
Median analyst target
$33
Analysts covering
14
Revenue$263.7M+45.4% y/y
Operating income$26.9M
Net income−$637K
Free cash flow$6.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+11.6%
1M
+16.1%
YTD
+12.1%
1Y
−0.3%
From 52W high
−6.2%
From 52W low
+107.9%
$15
$32
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CAI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Caris Life Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
79
Value
73
Quality
71
Momentum
46
Growth
45
Accruals
32
Volatility
32
Issuance
19
Size
17

Revisions (79): Analysts have, on balance, been raising their forecasts.

Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.

Size (17): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CAI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CAI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35$40Jan 26Apr 26Jul 26Oct 26CAIHigh $38Median $33Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
10 Buy4 Hold0 Sell
Low $22Median $33High $38

The green dot is the last close — the median target sits +9.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
14 Oct 2026JP MorganMaintainsOverweight$25 → $35
13 Oct 2026TD CowenMaintainsBuy$30 → $36
9 Sept 2026UBSInitiatesNeutral$28
6 Aug 2026BTIGMaintainsBuy—
6 Aug 2026BTIGMaintainsBuy$32 → $33
6 Aug 2026Evercore ISI GroupMaintainsOutperform—
6 Aug 2026Evercore ISI GroupMaintainsOutperform$25 → $26
5 Aug 2026JP MorganMaintainsOverweight—
6 July 2026Evercore ISI GroupMaintainsOutperform$30 → $25
6 July 2026Evercore ISI GroupMaintainsOutperform—
2 July 2026BTIGReiteratesBuy$32
2 July 2026BTIGReiteratesBuy—
2 June 2026Wolfe ResearchAssumesPeer Perform—
8 May 2026BTIGMaintainsBuy—
8 May 2026CitigroupMaintainsBuy—
8 May 2026JP MorganMaintainsOverweight—
13 Apr 2026JefferiesInitiatesBuy—
10 Apr 2026Piper SandlerInitiatesNeutral—
6 Apr 2026Evercore ISI GroupMaintainsOutperform—
13 Mar 2026Canaccord GenuityMaintainsHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CAI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CAI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Caris Life Sciences, Inc. returned −0.3% against +17.5% for the S&P 500, dividends included.

CAI vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26CAIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CAI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.7%
Analysts raising
4
Analysts cutting
4
Fundamentals

Caris Life Sciences, Inc. (CAI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
17.9×

Cheaper than 40% of US stocks

Price / sales
8.6×

Cheaper than 15% of US stocks

Price / book
14.4×

Cheaper than 6% of US stocks

EV / EBITDA
47.2×

Cheaper than 5% of US stocks

Growth & margins
Revenue growth (YoY)
45.4%

Higher than 84% of US stocks

Earnings growth (YoY)
45.4%

Higher than 73% of US stocks

Gross margin
68.1%

Higher than 81% of US stocks

Operating margin
10.2%

Higher than 64% of US stocks

Net margin
10.6%

Higher than 71% of US stocks

Returns & dividend
Return on equity
20.1%

Higher than 81% of US stocks

Return on assets
8.8%

Higher than 90% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Caris Life Sciences, Inc. (CAI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Caris Life Sciences, Inc. has a market value of $8.5B and an enterprise value of $8.2B.

  • Revenue in the twelve months to 30 June 2026: $989.6M. The latest quarter grew 45.4% year on year.

  • Net income over the same four quarters: $105.1M, a 10.6% net margin.

  • Diluted earnings per share, trailing twelve months: $0.36.

  • Free cash flow in the twelve months to 30 June 2026: $124.0M.

  • Caris Life Sciences, Inc. spent $21.5M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 282.6M.

  • Trailing P/E: 17.9×; forward P/E: 81.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Caris Life Sciences, Inc. employs 1,846 people — $536K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Oct 2026

Data provided by Twelve Data

Peers

CAI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CAICaris Life Sciences, Inc.$8.5B
41
TGTXTG Therapeutics, Inc.$8.6B
71
PTGXProtagonist Therapeutics, Inc.$8.7B
97
AXSMAxsome Therapeutics, Inc.$8.3B
70
CYTKCytokinetics, Inc.$8.8B
47
KYMRKymera Therapeutics, Inc.$8.9B
74
ARWRArrowhead Pharmaceuticals, Inc.$8.2B
53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Caris Life Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CAI news & analysis

Caris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026

PRNewsWire · 14 Oct 2026positive

Caris Life Sciences and the Caris Precision Oncology Alliance will present eight posters at the ESMO Congress 2026 in Madrid, October 23–27. The studies address AI-driven treatment prediction, risk stratification and biomarker discovery, using molecular profiling and multimodal data across multiple cancer types.

Why it matters — The presentations highlight Caris’s research activity in applying AI and integrated molecular data to precision oncology.

IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months

Investors Business Daily · 2 Oct 2026neutral

Caris Life Sciences stock is pulling back after more than doubling in value within two months. The report suggests waiting for the IPO stock to offer a new buy point.

Why it matters — A CAI watcher would care because this notes the stock's recent sharp run-up and its subsequent pullback, which could signal a new entry opportunity.

FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.

Market Watch · 23 Sept 2026neutral

FDA advisers are reviewing Grail's Galleri multicancer-detection test, which screens for 50 cancers from a blood draw, though a major study failed to prove it could detect later-stage cancers. Medicare coverage could follow pending the review.

Why it matters — CAI watchers would monitor this since regulatory and Medicare decisions on multicancer-detection tests could shape the competitive landscape for similar diagnostics.

Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Look

Investors Business Daily · 22 Sept 2026positive

Investors Business Daily reports that Caris Life Sciences has moved past a buy point, drawing attention to the Texas biotech researcher. Wall Street projects the company turning a net profit of 12 cents a share this year.

Why it matters — The piece highlights Caris Life Sciences crossing a key stock-momentum threshold and analysts' expectation of turning profitable, which a CAI watcher would view as a notable market and financial milestone.

Caris Life Sciences: Diagnostics Growth With Room To Run

Seeking Alpha · 17 Sept 2026positive

Caris Life Sciences is described as having an established profiling business that provides revenue and cash flows to support its expanding diagnostics portfolio. The article notes the company leverages molecular data and clinical relationships to develop new tests and that its Detect offering broadens growth potential, while noting it remains to be seen whether cash-pay adoption and marketing expenses pay off.

Why it matters — This item highlights CAI's existing revenue base and the growth potential of its diagnostics pipeline, which could be relevant to watchers tracking the company's expansion strategy.

FAQ

Frequently asked questions about CAI stock

What is the CAI stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Caris Life Sciences, Inc. have a median 12-month price target of $33, with estimates ranging from $22 to $38. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CAI stock a buy right now?

Of the 14 analysts covering Caris Life Sciences, Inc., 10 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Caris Life Sciences, Inc. 41 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CAI?

As at 14 Oct 2026, Caris Life Sciences, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (79 of 100).

Will CAI stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +9.1% from the last close, and Ticker Nerd's factor model ranks Caris Life Sciences, Inc. 41 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CAI stock forecast for 2030?

No analyst covering Caris Life Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CAI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $38 over the next 12 months.

How has CAI stock performed over the past year?

Caris Life Sciences, Inc. returned -0.3% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Caris Life Sciences, Inc. do?

Caris Life Sciences, Inc. Common Stock is the equity of Caris Life Sciences, a precision medicine and diagnostics company focused on molecular profiling and anatomic pathology services.

What is the latest news on CAI?

The most recent item we track (PRNewsWire, 14 Oct 2026): "Caris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026". Caris Life Sciences and the Caris Precision Oncology Alliance will present eight posters at the ESMO Congress 2026 in Madrid, October 23–27. The studies address AI-driven treatment prediction, risk stratification and biomarker discovery, using molecular profiling and multimodal data across multiple cancer types.

Company

About Caris Life Sciences, Inc.

Caris Life Sciences, Inc. Common Stock is the equity of Caris Life Sciences, a precision medicine and diagnostics company focused on molecular profiling and anatomic pathology services. The company uses advanced molecular information and artificial intelligence to help support cancer detection, disease characterization, treatment selection, and recurrence monitoring. Its current portfolio includes tissue-based and blood-based testing solutions, alongside software-driven tools designed to integrate clinical and molecular data for healthcare providers. Caris Life Sciences serves medical practices, laboratories, researchers, and biopharmaceutical partners across the United States and international markets. Headquartered in Irving, Texas, Caris Life Sciences operates at the intersection of biotechnology, data analytics, and clinical diagnostics, making it an important participant in the healthcare technology market.

CEO Dr. David Dean Halbert M.D. · 1,846 employees · United States · https://www.carislifesciences.com